We have also revealed the potential therapeutic value of targeting SMUG1, NTHL1, PARP3, NTRK1, YTHDF2, PDK1, CD274, HEY1, PDCD10 and MAGEA1 which are differentially expressed in cisplatin‐resistant NSCLC cells. This evidence concerns the gene MAGEA1 and non-small cell lung carcinoma.